Patients who have an IPMN surgically resected need to be followed clinically. The team from Hopkins recently reported their experience with close to 450 patients who had an intraductal papillary mucinous neoplasm (IPMN) of the pancreas resected. In the study, reported in the Annals of Surgery (PMID 33201121), the authors clinically followed 449 consecutive patients who had a non-invasive IPMN surgically resected at Johns Hopkins between 1995 and 2018. Remarkably, 16 (3.6%) of the patients developed an invasive cancer in their remnant pancreas during the period of follow-up. The authors estimated the risk of progression was 6.4% at five years after surgery, and 12.9% at 10 years after surgery. These results add to the growing body of evidence that suggest that patients should be clinically followed after they have had surgery for an IPMN because they have a small, but real, risk of developing cancer in their remnant pancreas.